Your browser doesn't support javascript.
loading
Factors associated with early, late, and very late stent thrombosis among patients with acute coronary syndrome undergoing coronary stent placement: analysis from the ATLAS ACS 2-TIMI 51 trial.
Chi, Gerald; AlKhalfan, Fahad; Lee, Jane J; Montazerin, Sahar Memar; Fitzgerald, Clara; Korjian, Serge; Omar, Wally; Barnathan, Elliot; Plotnikov, Alexei; Gibson, C Michael.
Affiliation
  • Chi G; Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States.
  • AlKhalfan F; Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States.
  • Lee JJ; Department of Trial Design and Development, Baim Institute for Clinical Research, Boston, MA, United States.
  • Montazerin SM; Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States.
  • Fitzgerald C; Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States.
  • Korjian S; Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States.
  • Omar W; Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States.
  • Barnathan E; Cardiovascular, Metabolism, Retina and Pulmonary Hypertension, Johnson & Johnson Pharmaceutical Research and Development, Raritan, NJ, United States.
  • Plotnikov A; Cardiovascular, Metabolism, Retina and Pulmonary Hypertension, Johnson & Johnson Pharmaceutical Research and Development, Raritan, NJ, United States.
  • Gibson CM; Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States.
Front Cardiovasc Med ; 10: 1269011, 2023.
Article in En | MEDLINE | ID: mdl-38259304
ABSTRACT

Background:

Stent thrombosis (ST) is an uncommon but serious complication of stent implantation. This study aimed to explore factors associated with early, late, and very late ST to help guide risk assessment and clinical decision-making on ST.

Methods:

The analysis included patients who received stent placement for the index acute coronary syndrome (ACS). Cumulative incidence of ST was assessed at 30 days (early ST), 31-360 days (late ST), 361-720 days (very late ST), and up to 720 days. Cox proportional hazards models were used to assess associations between ST and various factors, including patient characteristics [i.e., age, sex, ACS presentation, history of hypertension, smoking, diabetes, prior myocardial infarction (MI), heart failure, prior ischemic stroke, and cancer], laboratory tests [i.e., positive cardiac biomarker, hemoglobin, platelet count, white blood cell (WBC) count], and treatment [i.e., drug-eluting stent (DES) vs. bare-metal stent (BMS) and anticoagulant with rivaroxaban vs. placebo].

Results:

Among the 8,741 stented patients, 155 ST events (2.25%) occurred by Day 720. The cumulative incidences of early, late, and very late ST were 0.80%, 0.81%, and 0.77%, respectively. After multivariable adjustment, age ≥ 75 [hazard ratio (HR) = 2.13 (95% confidence interval, CI 1.26-3.60)], a history of prior MI [HR = 1.81 (95% CI 1.22-2.68)], low hemoglobin level [HR = 2.34 (95% CI 1.59-3.44)], and high WBC count [HR = 1.58 (95% CI 1.02-2.46)] were associated with a greater risk of overall ST, whereas DES [HR = 0.56 (95% CI 0.38-0.83)] and rivaroxaban therapy [HR = 0.63 (95% CI 0.44-0.88)] were associated with a lower risk of overall ST up to 720 days. Low hemoglobin level and high WBC count were associated with early ST (low hemoglobin HR = 2.35 [95% CI 1.34-4.12]; high WBC count HR = 2.11 [95% CI 1.17-3.81]). Low hemoglobin level and prior MI were associated with a greater risk of late ST (low hemoglobin HR = 2.32 [95% CI 1.26-4.27]; prior MI HR = 2.98 [95% CI 1.67-5.31]), whereas DES was associated with a lower risk of late ST [HR = 0.33 (95% CI 0.16-0.67)]. Age ≥75 years was associated with very late ST.

Conclusion:

The study identified positive and negative associations with early, late, and very late ST. These variables may be useful in constructing risk assessment models for ST. Clinical Trial Registration http//www.clinicaltrials.gov, identifier NCT00809965.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Language: En Journal: Front Cardiovasc Med Year: 2023 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Language: En Journal: Front Cardiovasc Med Year: 2023 Document type: Article Affiliation country: Country of publication: